Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates

Sana Biotechnology, Inc.

2022-Q3 EPS reported -$1.01

Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.
Cash runway expected into 2025; operating cash burn $219.8M for nine months ended Sep 30, 2022.
SC291 (allogeneic CAR T) IND filing on track for 2022 with clinical data expected in 2023.
SG295 (in vivo CAR T) IND filing delayed to 2023 to incorporate second-generation process with 50X potency improvement.
SC276 IND on track for 2023; SC451 (type 1 diabetes cell therapy) IND expected in 2024 with data in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for the quarter and year ended September 30, 2022.

Period: the quarter and year ended September 30, 2022
Result: reported results

Exact text from the filing

On November 2, 2022, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended September 30, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-036367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.